3 Sources
[1]
Isomorphic Labs and MSD team up on AI-led cancer drug discovery
The partnership will see both organisations collaborate on oncology drug therapies designed to target specific molecules. Alphabet's Isomorphic Labs and MSD are set to collaborate on a research project that will combine Isomorphic Labs' AI technology with MSD's data resources. The partnership
[2]
Merck partners with Isomorphic Labs on AI-based research
Merck (MSD outside North America) announced a research collaboration with Isomorphic Labs, a company specializing in the design and development of artificial intelligence (AI)-based medicines. Both companies will collaborate on the discovery of small-molecule therapeutic candidates targeting a
[3]
Merck Enters Strategic Research Collaboration with Isomorphic Labs
Merck announced a research collaboration with Isomorphic Labs that brings together Isomorphic Labs? AI approach to drug discovery with Merck?s proprietary data resources and discovery experience. The companies will collaborate to discover therapeutic small molecule candidates against an oncology
Share
Copy Link
Merck is teaming up with Isomorphic Labs, the Alphabet-owned company specializing in AI-based drug design, to find new cancer drug candidates, the companies announced this week
3
2
1
.
Source: Market Screener
The collaboration covers a single cancer target, which the companies describe as of strategic importance but do not name. It looks only for small-molecule drug candidates against it
3
2
1
.Isomorphic will do the early work on computers, using its own drug design engine, called IsoDDE, to predict and design molecules. That engine will draw on a selection of Merck's proprietary datasets, supplied specifically for this collaboration
3
1
. Everything after that stays with Merck: the New Jersey company keeps preclinical and clinical development, manufacturing and, if a drug emerges, selling it2
1
.
Source: Silicon Republic
Isomorphic gets an upfront payment plus milestone payments tied to research, development, regulatory and commercial progress, and tiered royalties on any sales. None of the amounts were disclosed
3
2
. Isomorphic also holds an option to help fund development work in exchange for higher royalties3
1
.The deal lands days after Isomorphic announced a $5bn funding round, per Silicon Republic, co-led by Greenoaks and Sequoia Capital with backing from Alphabet, Andreessen Horowitz and existing investors including Thrive Capital and Temasek
1
.Isomorphic chief research officer Sarah Skerratt said the deal would "unlock significant discovery progress" for patients whose needs current drugs do not meet
1
. George Addona, who runs discovery research at Merck, has said that making AI drug design work depends on close coordination between lab experiments and computer modelling. Pairing Merck's data with Isomorphic's modelling and computing power, he said, aims to produce better drug candidates faster1
.Related Stories
Summarized by
Navi
[1]
[2]
[3]
17 Nov 2026•Business and Economy

09 May 2026•Startups

31 Mar 2025•Business and Economy
